ACM
PMN icon

Altium Capital Management’s ProMIS Neurosciences PMN Stock Holding History

Altium Capital Management’s Portfolio PMN Stock Details PMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,970
Closed -$399K – 12
2025
Q1 		$399K Sell
22,970
-286
-1% -$6.07K 0.96% 16
2024
Q4 		$551K Hold
23,256
– – 0.16% 57
2024
Q3 		$727K Buy
+23,256
New +$868K 0.21% 51

Other funds holding PMN

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
AI
Allostery Investments Stamford, Connecticut $7.85M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GL
Graypoint LLC Albany, New York $1.78B AUM 16.72% 1-Year Est. Return
KWM
Kingsview Wealth Management Grants Pass, Oregon $7.33B AUM 16.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return

Altium Capital Management's PMN Position: Q2 2025 in Review

Altium Capital Management sold out of ProMIS Neurosciences (PMN) in Q2 2025, closing a stake of 22,970 shares — an estimated $399K sold.

Altium Capital Management first reported a position in PMN in Q3 2024 and held it in 3 quarters. The position peaked at $727K in Q3 2024. 19 funds tracked by Wall St. Rank hold PMN as of Q2 2025.

  • Altium Capital Management reported no remaining ProMIS Neurosciences position as of Q2 2025 after selling out during the quarter.
  • Altium Capital Management sold 22,970 ProMIS Neurosciences shares in Q2 2025, an estimated $399K.
  • Altium Capital Management first reported a position in ProMIS Neurosciences in Q3 2024 and held it in 3 quarters.
  • Altium Capital Management's ProMIS Neurosciences position peaked at $727K in Q3 2024.
  • 19 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q2 2025.

Based on Altium Capital Management's 13F filing for Q2 2025.